glp 1 drugs and parkinson's disease GLP-1 Disease: Research, Benefits and Risks An update on drug repurposing

Identified as the first incretin in the 1970s (see section I), GIP has historically been thought to have little therapeutic potential

But researchers arent done sharpening the edge

Diabetes Care 44(6):14431446

Recent rodent studies have also generated evidence suggesting that GIP action through GIPR lowers body weight and food intake via central neuronal signalling, given that these effects were not observed in CNS-GIPR knockout mice

gratefully acknowledges support from the Simons Foundation

Mechanistically, GLP-1RAs suppress neuroinflammation by shifting microglia from a pro-inflammatory to a phagocytic, anti-inflammatory phenotype